FDA Approves Monthly Maintenance Dosing for Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved a monthly maintenance dosing regimen for Leqembi, an Alzheimer’s drug developed by Japan’s Eisai and its partner Biogen, the companies announced on Monday. The decision is expected to improve treatment convenience for patients.